Skip to content

Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients

Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01042392
Acronym
ALIAS
Enrollment
506
Registered
2010-01-05
Start date
2009-11-30
Completion date
2011-01-31
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Keywords

Moderate systolic hypertension - adults - aliskiren -ramipril

Brief summary

This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.

Interventions

DRUGAliskiren

150 mg Aliskiren as film-coated tablet

DRUGRamipril

Ramipril 5 mg was given in capsule form.

DRUGMatching placebo to Aliskiren

The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.

DRUGMatching placebo to Ramipril

The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.

Sponsors

Novartis
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Outpatients \> 18 years * Male or female patients. Female patients must have been either post-menopausal for one year, surgically sterile, or using effective contraceptive methods * Patients with essential hypertension, previously treated with an antihypertensive single-drug therapy, either uncontrolled or intolerant. * BP thresholds at visit 1: * For patients previously treated and uncontrolled: 140≤ office SBP\<180 mmHg * For patients previously treated, controlled but intolerant: office SBP≥130 mmHg * BP thresholds at visit 2 (for all patients): * 160≤office SBP\<180 mmHg AND * 155≤home SBP\<175 mmHg (3-day period of home blood pressure monitoring just before randomization)

Exclusion criteria

* Women of child-bearing potential not using any effective methods of contraception * Severe hypertension (office BP ≥ 180/110 mmHg) * Impossibility to stop abruptly previous antihypertensive treatments at visit 1 * Patients previously untreated or patients treated with two or three antihypertensive medications * History or evidence of a secondary form of hypertension * History of hypersensitivity to ACEi or renin inhibitors * History of heart failure, stroke or coronary heart disease * Serum potassium ≥ 5.2 mmol/l Other protocol-defined inclusion/

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)Baseline to 8 weeksThe arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of covariance included treatment factor and baseline mean sitting SBP as covariable.

Secondary

MeasureTime frameDescription
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)Baseline to 8 weeksThe arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of variance included treatment factor and baseline value of mean sitting DBP as covariable.
Percentage of Patients With Controlled Blood PressureAt 4 and 8 weeksThe arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. Controlled blood pressure (BP) is defined as mean office systolic BP/ diastolic BP \< 140/90 mmHg.
Number of the Participants With More Than 55 mmHg Difference Between the Mean SBP Measured at the Morning Surge and the Mean Minimal SBP Measured During the NightAfter 8 weeksAmbulatory blood pressure measurement (ABPM) over 24 hours was performed for all patients on the day before visit 4, the device attached to the ambulatory blood pressure non-dominant arm of the patient. The BP morning surge was defined as the average of the measurements taken during the first 2 hours after waking the patient. The minimal night blood pressure was defined as the average of the two lowest BP measures (the lowest hourly average) recorded during night time.
Change in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks)Baseline to 4 weeksThe arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of covariance included treatment factor and baseline mean sitting SBP and mean sitting DBP as covariables.
Difference Between the Maximal and the Minimal Mean-hour SPB Measured Between 1 and 8 am at Week 8At week 8Ambulatory blood pressure measurement (ABPM) over 24 hours was performed for all patients on the eve of visit 4 (week 8), the device attached to the ambulatory blood pressure non-dominant arm of the patient. The difference between mean-hour maximum SBP mean-hour minimum SBP between 1 am and 8 am was measured.
Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Baseline to 8 weeksThe sub-groups were: Riser = patients with \>= 55 mmHg difference between the mean SPB measured at the morning surge and the mean minimal SBP measured during the night. The Non-risers in whom the difference is \<55 mmHg. Patients called dippers in whom there was a decrease in average nocturnal SBP ≥ 10% compared with average daytime SBP, in contrast to patients non-dippers in whom this difference was \<10%.
Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-doseFrom 8 weeks to 48 hours after week 8The change in blood pressure was measured between visit 4 (end of the period of double-blind active treatment which was at week 8) and visit 5 (48 hours after the last active dose taken) in the group of patients who received aliskiren or placebo and those who received ramipril or placebo. The analysis of covariance included treatment factor and baseline mean sitting SBP and mean sitting DBP as covariables.
Number Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III)8 weeks + 1 dayAdverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.

Countries

France

Participant flow

Participants by arm

ArmCount
Ramipril
In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in. In period II (double-blind treatment, randomized): Ramipril 5 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to Ramipril 10 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4. In period III (double-blind withdrawal): At visit 4, patients received placebo or the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4).
257
Aliskiren
In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in. In period II (double-blind treatment, randomized): Aliskiren 150 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to aliskiren 300 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4. In period III (double-blind withdrawal): At visit 4, patients received placebo or the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4).
249
Total506

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Period III (Unblinded,Controlled, 1 Day)Administrative problems0111
Period III (Unblinded,Controlled, 1 Day)Adverse Event0010
Period III (Unblinded,Controlled, 1 Day)Protocol Violation2000
Period III (Unblinded,Controlled, 1 Day)Withdrawal by Subject0020
Period II(Randomized,Double Blinded,8wk)Administrative problems2000
Period II(Randomized,Double Blinded,8wk)Adverse Event6050
Period II(Randomized,Double Blinded,8wk)Lost to Follow-up0010
Period II(Randomized,Double Blinded,8wk)Unsatisfactory therapeutic effect1000
Period II(Randomized,Double Blinded,8wk)Withdrawal by Subject1020

Baseline characteristics

CharacteristicAliskirenRamiprilTotal
Age Continuous61.0 years
STANDARD_DEVIATION 11.4
59.8 years
STANDARD_DEVIATION 11.6
60.4 years
STANDARD_DEVIATION 11.5
Age, Customized
50 - 64 years
115 Participants119 Participants234 Participants
Age, Customized
< 50 years
39 Participants56 Participants95 Participants
Age, Customized
65 - 74 years
64 Participants56 Participants120 Participants
Age, Customized
>= 75 years
31 Participants26 Participants57 Participants
Sex: Female, Male
Female
133 Participants142 Participants275 Participants
Sex: Female, Male
Male
116 Participants115 Participants231 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —
other
Total, other adverse events
0 / 2570 / 1180 / 2480 / 122
serious
Total, serious adverse events
3 / 2570 / 1181 / 2480 / 122

Outcome results

Primary

Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)

The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of covariance included treatment factor and baseline mean sitting SBP as covariable.

Time frame: Baseline to 8 weeks

Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
RamiprilChange From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)-18.80 mmHgStandard Error 0.92
AliskirenChange From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)-20.78 mmHgStandard Error 0.92
Secondary

Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)

The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of variance included treatment factor and baseline value of mean sitting DBP as covariable.

Time frame: Baseline to 8 weeks

Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5. Patients with observation at both time points were included in this analysis.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
RamiprilChange From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)-5.23 mmHgStandard Error 0.6
AliskirenChange From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)-6.39 mmHgStandard Error 0.6
Secondary

Change in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)

The sub-groups were: Riser = patients with \>= 55 mmHg difference between the mean SPB measured at the morning surge and the mean minimal SBP measured during the night. The Non-risers in whom the difference is \<55 mmHg. Patients called dippers in whom there was a decrease in average nocturnal SBP ≥ 10% compared with average daytime SBP, in contrast to patients non-dippers in whom this difference was \<10%.

Time frame: Baseline to 8 weeks

Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5. Patients with observation at different categories were included in this analysis.

ArmMeasureGroupValue (MEAN)Dispersion
RamiprilChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msSBP: Risers (n= 3, 9)-19.7 mmHgStandard Deviation 6.11
RamiprilChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msSBP: Non-risers (n=109, 103)-19.2 mmHgStandard Deviation 13.99
RamiprilChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msSBP: Dippers (n= 80, 94)-18.1 mmHgStandard Deviation 11.86
RamiprilChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msSBP: Non-dippers (n= 93, 92)-19.2 mmHgStandard Deviation 14.93
RamiprilChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msDBP: Risers (n= 3, 9)-7.3 mmHgStandard Deviation 10.6
RamiprilChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msDBP: Non-risers(n=109, 103)-4.2 mmHgStandard Deviation 9.51
RamiprilChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msDBP: Dippers (n= 80, 94)-5.5 mmHgStandard Deviation 9.63
RamiprilChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msDBP: Non-dippers (n= 93, 92)-5.3 mmHgStandard Deviation 9.59
AliskirenChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msDBP: Non-dippers (n= 93, 92)-6.5 mmHgStandard Deviation 9.56
AliskirenChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msSBP: Risers (n= 3, 9)-16.9 mmHgStandard Deviation 10.52
AliskirenChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msDBP: Risers (n= 3, 9)-6.6 mmHgStandard Deviation 9.11
AliskirenChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msSBP: Non-risers (n=109, 103)-20.5 mmHgStandard Deviation 14.49
AliskirenChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msDBP: Dippers (n= 80, 94)-6.3 mmHgStandard Deviation 9.81
AliskirenChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msSBP: Dippers (n= 80, 94)-19.8 mmHgStandard Deviation 12.05
AliskirenChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msDBP: Non-risers(n=109, 103)-5.7 mmHgStandard Deviation 9.61
AliskirenChange in Mean Sitting DBP and SBP in Specified Sub-groups From Visit 2 (Baseline) to Visit 4 (at 8 Weeks)Change in msSBP: Non-dippers (n= 93, 92)-21.1 mmHgStandard Deviation 15.06
Secondary

Change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-dose

The change in blood pressure was measured between visit 4 (end of the period of double-blind active treatment which was at week 8) and visit 5 (48 hours after the last active dose taken) in the group of patients who received aliskiren or placebo and those who received ramipril or placebo. The analysis of covariance included treatment factor and baseline mean sitting SBP and mean sitting DBP as covariables.

Time frame: From 8 weeks to 48 hours after week 8

Population: Per-protocol missed dose population included all per protocol population patients who had received the study treatment for period 3 according to the protocol (duration of period 3 and treatment intake). Patients with observation at both time points were included in this analysis.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
RamiprilChange in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-doseChange in msSBP-0.50 mmHgStandard Error 1.05
RamiprilChange in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-doseChange in msDBP0.76 mmHgStandard Error 0.69
AliskirenChange in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-doseChange in msDBP0.32 mmHgStandard Error 0.79
AliskirenChange in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-doseChange in msSBP-1.28 mmHgStandard Error 1.1
AliskirenChange in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-doseChange in msSBP0.52 mmHgStandard Error 1.06
AliskirenChange in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-doseChange in msDBP-0.40 mmHgStandard Error 0.78
Placebo to AliskirenChange in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-doseChange in msSBP3.27 mmHgStandard Error 1.1
Placebo to AliskirenChange in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP) From Last Active Dose Taken to After a One-day Missed-doseChange in msDBP0.97 mmHgStandard Error 0.81
Secondary

Change in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks)

The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. The analysis of covariance included treatment factor and baseline mean sitting SBP and mean sitting DBP as covariables.

Time frame: Baseline to 4 weeks

Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
RamiprilChange in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks)Change in msSBP-19.42 mmHgStandard Error 0.92
RamiprilChange in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks)Change in msDBP-5.37 mmHgStandard Error 0.56
AliskirenChange in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks)Change in msSBP-19.75 mmHgStandard Error 0.92
AliskirenChange in msSBP and msDBP From Visit 2 (Baseline) to Visit 3 (at 4 Weeks)Change in msDBP-5.60 mmHgStandard Error 0.56
Secondary

Difference Between the Maximal and the Minimal Mean-hour SPB Measured Between 1 and 8 am at Week 8

Ambulatory blood pressure measurement (ABPM) over 24 hours was performed for all patients on the eve of visit 4 (week 8), the device attached to the ambulatory blood pressure non-dominant arm of the patient. The difference between mean-hour maximum SBP mean-hour minimum SBP between 1 am and 8 am was measured.

Time frame: At week 8

Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5. Patients with ABPM measurements over 24 hours were included in this analysis.

ArmMeasureValue (MEAN)Dispersion
RamiprilDifference Between the Maximal and the Minimal Mean-hour SPB Measured Between 1 and 8 am at Week 833.6 mmHgStandard Deviation 14.04
AliskirenDifference Between the Maximal and the Minimal Mean-hour SPB Measured Between 1 and 8 am at Week 835.5 mmHgStandard Deviation 15.05
Secondary

Number of the Participants With More Than 55 mmHg Difference Between the Mean SBP Measured at the Morning Surge and the Mean Minimal SBP Measured During the Night

Ambulatory blood pressure measurement (ABPM) over 24 hours was performed for all patients on the day before visit 4, the device attached to the ambulatory blood pressure non-dominant arm of the patient. The BP morning surge was defined as the average of the measurements taken during the first 2 hours after waking the patient. The minimal night blood pressure was defined as the average of the two lowest BP measures (the lowest hourly average) recorded during night time.

Time frame: After 8 weeks

Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5. Patients with ABPM to evaluate the occurrence or absence of a morning peak were included in this analysis.

ArmMeasureValue (NUMBER)
RamiprilNumber of the Participants With More Than 55 mmHg Difference Between the Mean SBP Measured at the Morning Surge and the Mean Minimal SBP Measured During the Night3 Participants
AliskirenNumber of the Participants With More Than 55 mmHg Difference Between the Mean SBP Measured at the Morning Surge and the Mean Minimal SBP Measured During the Night9 Participants
Secondary

Number Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III)

Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.

Time frame: 8 weeks + 1 day

Population: All randomized patients except one patient from Aliskiren arm who was lost to follow up after visit 2.

ArmMeasureGroupValue (NUMBER)
RamiprilNumber Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III)Patients with at least 1 AE55 Participants
RamiprilNumber Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III)Patients with at least 1 SAE3 Participants
RamiprilNumber Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III)Death0 Participants
AliskirenNumber Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III)Patients with at least 1 AE43 Participants
AliskirenNumber Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III)Patients with at least 1 SAE1 Participants
AliskirenNumber Patients Reported With Adverse Events (AEs), Serious Adverse Events (SAE) and Death (Period II and Period III)Death0 Participants
Secondary

Percentage of Patients With Controlled Blood Pressure

The arm in which the highest sitting systolic blood pressure (SBP) was found at study entry was used for all subsequent readings. At each study visit, after leaving the patient to rest 5 minutes in a sitting position, the blood pressure (BP) was measured three times with an oscillometric device. The measurements were performed at 1-2 minute intervals. The mean BP was calculated from the 3 readings. Controlled blood pressure (BP) is defined as mean office systolic BP/ diastolic BP \< 140/90 mmHg.

Time frame: At 4 and 8 weeks

Population: Intent to treat population included all randomized patients who had received at least one dose of study drug. It also excluded all those patients from centers that reported more than 90% of BP measurements rounded to 0 or 5. Patients with observation at each time point were included in this analysis.

ArmMeasureGroupValue (NUMBER)
RamiprilPercentage of Patients With Controlled Blood PressureAt week 4 (N= 218, 217)36.7 Percentage
RamiprilPercentage of Patients With Controlled Blood PressureAt week 8 (N= 213, 213)26.8 Percentage
AliskirenPercentage of Patients With Controlled Blood PressureAt week 4 (N= 218, 217)40.1 Percentage
AliskirenPercentage of Patients With Controlled Blood PressureAt week 8 (N= 213, 213)32.4 Percentage

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026